Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13718-13727
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13718
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13718
Figure 1 Experimental arms for INT0116, MAGIC and CALGB 80101 study.
ECF: Epirubicin, cisplatin, 5-fluoro-uracil; LV: Leucovorin; FU/LV: Fluorouracil/leucovorin; CT: Chemotherapy; CRT: Chemo-radiotherapy.
Figure 2 Experimental arms of CRITICS and TOPGEAR trials.
ECC: Epirubicin, cisplatin and capecitabine; CRT: Chemo-radiotherapy; FU: Fluorouracil; ECF: Epirubicin, cisplatin, 5-FU; LV: Leucovorin; CT: Chemotherapy.
- Citation: Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13718.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13718